哈卡特
渗透
角质层
体内
粒径
银屑病
最后
材料科学
Zeta电位
泊洛沙姆
真皮
化学
色谱法
角质形成细胞
体外
纳米颗粒
纳米技术
皮肤病科
医学
膜
聚合物
有机化学
病理
生物化学
生物技术
物理化学
共聚物
银屑病性关节炎
生物
作者
Vamshi Krishna Rapalli,Yashika Tomar,Swati Sharma,Aniruddha Roy,Gautam Singhvi
标识
DOI:10.1016/j.biopha.2023.114634
摘要
The present work aimed to prepare and evaluate Apremilast loaded lyotropic liquid crystalline nanoparticles (LCNPs) formulation for skin delivery to enhance the efficacy with reduced adverse effects of the oral therapy in psoriasis treatment. The LCNPs were prepared using the emulsification using a high shear homogenizer for size reduction and optimized with Box Behnken design to achieve desired particle size and entrapment efficiency. The selected LCNPs formulation was evaluated for in-vitro release, in-vitro psoriasis efficacy, skin retention, dermatokinetic, in-vivo skin retention, and skin irritation study. The selected formulation exhibited 173.25 ± 2.192 nm (polydispersity 0.273 ± 0.008) particle size and 75.028 ± 0.235% entrapment efficiency. The in-vitro drug release showed the prolonged-release for 18 h. The ex-vivo studies revealed that LCNPs formulation exhibited drug retention up to 3.2 and 11.9-fold higher, in stratum corneum and viable epidermis compared to conventional gel preparation. In-vitro cell line studies performed on immortal keratinocyte cells (HaCaT cells) demonstrated non-toxicity of selected excipients used in designed LCNPs. The dermatokinetic study revealed the AUC0-24 of the LCNPs loaded gel was 8.4 fold higher in epidermis and 2.06 fold in dermis, respectively compared to plain gel. Further, in-vivo animal studies showed enhanced skin permeation and retention of Apremilast compared to conventional gel.
科研通智能强力驱动
Strongly Powered by AbleSci AI